v3.25.2
Segment Information
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases.
The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.
Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:
Three Months Ended June 30,
20252024
Revenue from collaborative arrangement$— $100,762 
Less:
Research and development:
     INO-31073,930,320 11,042,995 
     INO-3112 and other Immuno-oncology1,437,759 1,562,832 
     Other programs (a)153,488 203,562 
     Engineering and device-related5,084,662 4,838,666 
     Stock-based compensation321,688 590,102 
     Other unallocated expenses 3,593,490 4,852,832 
General and administrative8,563,112 10,206,686 
Total operating expenses23,084,519 33,297,675 
Interest income610,638 1,307,358 
Change in fair value of common stock warrant liability(1,878,010)— 
Gain (loss) on investment in affiliated entity776,373 (334,294)
Net unrealized gain (loss) on available-for-sale equity securities759,289 (20,820)
Other (expense) income, net(703,183)7,571 
Net loss$(23,519,412)$(32,237,098)
Six Months Ended June 30,
20252024
Revenue from collaborative arrangement$65,343 $100,762 
Less:
Research and development:
     INO-31077,437,662 18,688,659 
     INO-3112 and other Immuno-oncology2,752,843 3,583,582 
     Other programs (a)260,913 827,228 
     Engineering and device-related10,146,472 8,589,927 
     Stock-based compensation875,082 1,650,589 
     Other unallocated expenses 9,139,337 10,661,322 
General and administrative17,588,082 20,781,337 
Total operating expenses48,200,391 64,782,644 
Interest income1,418,715 2,807,648 
Interest expense— (177,833)
Change in fair value of common stock warrant liability1,834,862 — 
Gain (loss) on investment in affiliated entity1,471,504 (460,312)
Net unrealized gain on available-for-sale equity securities899,523 480,057 
Other expense, net(703,665)(674,647)
Net loss$(43,214,109)$(62,706,969)

(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.